Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer: A Phases Ib, Single Arm Study

NCT07674615 is registered in ClinicalTrials.gov with Shanghai Gynecologic Oncology Group as lead sponsor.

NCT NCT07674615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07674615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer: A Phases Ib, Single Arm Study
Lead sponsor
Shanghai Gynecologic Oncology Group
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
June 30, 2027
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancers, primary, primary peritoneal carcinoma